➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Dow
McKinsey
Colorcon
McKesson

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

MELOXICAM - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for meloxicam and what is the scope of patent protection?

Meloxicam is the generic ingredient in five branded drugs marketed by Lupin Ltd, Zyla, Baudax, Avondale Pharms, Tersera, Anda Repository, Apotex Inc, Aurobindo Pharma, Cipla, Cr Double Crane, Dr Reddys Labs Inc, Glenmark Generics, Heritage Pharma, Impax Labs Inc, Lupin Pharms, Mylan, Nostrum Labs Inc, Puracap Pharm, Roxane, Strides Pharma, Sun Pharm Inds Inc, Taro, Unichem, Yabao Pharm, Yung Shin Pharm, Zydus Pharms Usa, and Boehringer Ingelheim, and is included in twenty-eight NDAs. There are nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Meloxicam has fifty-one patent family members in twenty-three countries.

There are twenty-two drug master file entries for meloxicam. Thirty-four suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for MELOXICAM

See drug prices for MELOXICAM

Drug Sales Revenue Trends for MELOXICAM

See drug sales revenues for MELOXICAM

Recent Clinical Trials for MELOXICAM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Daewoong Pharmaceutical Co. LTD.Phase 1
Beijing Tongren HospitalPhase 1
Axsome Therapeutics, Inc.Phase 3

See all MELOXICAM clinical trials

Generic filers with tentative approvals for MELOXICAM
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial10MGCAPSULE;ORAL
  Start Trial  Start Trial5MGCAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for MELOXICAM
Paragraph IV (Patent) Challenges for MELOXICAM
Tradename Dosage Ingredient NDA Submissiondate
VIVLODEX CAPSULE;ORAL meloxicam 207233 2017-01-09
MOBIC SUSPENSION;ORAL meloxicam 021530 2009-12-17

US Patents and Regulatory Information for MELOXICAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heritage Pharma MELOXICAM meloxicam TABLET;ORAL 077936-001 Jul 19, 2006 DISCN No No   Start Trial   Start Trial   Start Trial
Cipla MELOXICAM meloxicam TABLET;ORAL 077929-002 Jul 19, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan MELOXICAM meloxicam TABLET;ORAL 077934-002 Jul 20, 2006 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Boehringer Ingelheim
Colorcon
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.